Showing 1291-1300 of 1616 results for "".
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-proposed-lucentis-biosimilar/2478376/Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular d
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- Visibly Offers Free Telehealth Vision Tests During COVID-19 Pandemichttps://modernod.com/news/visibly-offers-free-telehealth-vision-tests-during-covid-19-pandemic/2477627/Visibly announced that it will globally provide optometrists, ophthalmologists, and optical service providers free access to its virtual vision test technology to ensure that patients can meet their eye health needs during this unprecedented time. “We are thrilled to offer Visibly to all d
- ProtoKinetix AAGP Exhibits Efficacy and Safety in Model of Dry Eye Diseasehttps://modernod.com/news/protokinetix-aagp-exhibits-efficacy-and-safety-in-model-of-dry-eye-disease/2479530/ProtoKinetix, which recently announced filing for patent protection for new applications of its AAGP (PKX-001) molecule, announced preliminary results in efficacy and safety for use in treating dry eye disease (DED). PKX-001 demonstrated a protective effect in the murine model of dry eye d